| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 1.21 | 4.3% | 3.4% |
| Total Income | 1.21 | 4.3% | 3.4% |
| Expenditure | 12.97 | 3.4% | 0.8% |
| PBT | -10.40 | 134.2% | 15.9% |
| Net Profit | -10.40 | 134.2% | 15.9% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.10 | 25.0% | 60.0% |
Lucid Diagnostics Reports Q3 2025 Revenue of $1.2 Million
04 May 2026 · 4 May, 7:23 am
Summary
Lucid Diagnostics reported $1.2 million in EsoGuard revenue for Q3 2025. Operating expenses were approximately $13.0 million, including $1.2 million in stock-based compensation. The GAAP net loss attributable to common stockholders was approximately $10.4 million, or $(0.10) per common share. The company's cash and cash equivalents were $47.3 million as of September 30, 2025, compared to $22.4 million as of December 31, 2024.
Key Highlights
- 1
Lucid Diagnostics processed 2,841 EsoGuard® tests in Q3 2025.
- 2
The company recognized $1.2 million in EsoGuard® revenue for Q3 2025.
- 3
A Multi-Jurisdictional Contractor Advisory Committee meeting unanimously supported Medicare coverage for EsoGuard.
- 4
Lucid Diagnostics strengthened its balance sheet with a public offering, netting approximately $27.0 million in proceeds.
- 5
The company ended Q3 2025 with over $47 million in proforma cash, extending the runway through 2026.
- 6
Danielle Scelfo was appointed as Senior Vice President, Market Access & Government Affairs.
- 7
A Firefighter Esophageal Cancer Prevention Summit is scheduled for November 19–20.
Management Comments
Lishan Aklog
M.D.
“The overwhelmingly positive MolDx CAC meeting in September—with medical experts unanimously supporting Medicare coverage for EsoGuard—further reinforces our confidence that we are now firmly in the final stages of achieving this transformative coverage milestone,” “Our strengthened balance sheet, continued commercial execution, targeted initiatives aimed at the Medicare population, and a new world-class market access team driving payor engagement have us well-prepared to accelerate EsoGuard commercialization as Medicare coverage and other upcoming reimbursement milestones are secured.”
Informational and educational content only. Not investment advice.